{{Short description|Tumor that often causes a syndrome of diarrhea and electrolyte imbalance}} {{Infobox medical condition | name = VIPoma | synonyms = | image = | caption = | pronounce = | field = Oncology medicine | | symptoms = watery diarrhea, hypokalemia, achlorhydria. | complications = | onset = most patients are middle aged | duration = | types = usually solitary, 2/3 are malignant | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = bad. | frequency = | deaths = frequent. }}
A '''VIPoma''' or '''vipoma''' ({{IPAc-en|v|ɪ|ˈ|p|oʊ|m|ə}}) is a rare endocrine tumor<ref>{{DorlandsDict|nine/000116307|VIPoma}}</ref> that overproduces vasoactive intestinal peptide (thus ''VIP'' + ''-oma''). The incidence is about 1 per 10,000,000 per year. 90% of VIPomas originate from the non-β islet cells of the pancreas, sometimes associated with multiple endocrine neoplasia type 1. Roughly 50–75% of VIPomas are malignant, but even when they are benign, they are problematic because they tend to cause a specific syndrome: the massive amounts of secreted VIP overstimulates pancreatic bicarbonate and chloride secretion, and its binding to intestinal epithelial cells leads to sodium, chloride and water secretion into the bowel (secretory watery diarrhea, often >3L/day). all this causes a syndrome of profound and chronic watery diarrhea and resultant dehydration, hypokalemia, achlorhydria, acidosis, flushing and hypotension (from vasodilation), hypercalcemia, and hyperglycemia.<ref>{{cite journal |vauthors=Mansour JC, Chen H |title=Pancreatic endocrine tumors |journal=J Surg Res |volume=120 |issue=1 |pages=139–61 |date=Jul 2004 |pmid=15172200 |doi=10.1016/j.jss.2003.12.007 }}</ref><ref>{{Cite web|url=https://rarediseases.info.nih.gov/diseases/5493/vipoma|title=VIPoma {{!}} Genetic and Rare Diseases Information Center (GARD) – an NCATS Program|website=rarediseases.info.nih.gov|language=en|access-date=2018-04-17|archive-date=2018-04-18|archive-url=https://web.archive.org/web/20180418032119/https://rarediseases.info.nih.gov/diseases/5493/vipoma|url-status=dead}}</ref> This syndrome is called '''Verner–Morrison syndrome''' ('''VMS'''), '''WDHA syndrome''' (from watery diarrhea–hypokalemia–achlorhydria), or '''pancreatic cholera syndrome''' ('''PCS'''). The eponym reflects the physicians who first described the syndrome.<ref>{{cite journal |vauthors=Verner JV, Morrison AB |title=Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia |journal=Am J Med |volume=25 |issue=3 |pages=374–80 |date=Sep 1958 |pmid=13571250 |doi= 10.1016/0002-9343(58)90075-5}}</ref>
==Symptoms and signs== The major clinical features are prolonged watery diarrhea (fasting stool volume > 750 to 1000 mL/day) and symptoms of hypokalemia and dehydration. Half of the patients have relatively constant diarrhea while the rest have alternating periods of severe and moderate diarrhea. One third have diarrhea < 1yr before diagnosis, but in 25%, diarrhea is present for 5 yr or more before diagnosis. Lethargy, muscle weakness, nausea, vomiting and crampy abdominal pain are frequent symptoms. Hypokalemia and impaired glucose tolerance occur in < 50% of patients. Achlorhydria is also a feature. During attacks of diarrhea, flushing similar to the carcinoid syndrome occur rarely.<ref>{{cite web |url=https://www.lecturio.com/concepts/carcinoid-tumors-and-syndrome/ | title= Carcinoid Tumors and Syndrome | website= The Lecturio Medical Concept Library |access-date= 5 July 2021}}</ref>
==Diagnosis== Besides the clinical picture, fasting VIP plasma level may confirm the diagnosis, and CT scan and somatostatin receptor scintigraphy are used to localise the tumor, which is usually metastatic at presentation.<ref name="auto">{{cite journal | vauthors= Sandhu S, Jialal I | url=https://www.ncbi.nlm.nih.gov/books/NBK507698/ | title= ViPoma | website= National Center for Biotechnology Information, U.S. National Library of Medicine | date=2024 | pmid=29939520 |access-date= 5 July 2021}}</ref>
Tests include: * Blood chemistry tests (basic or comprehensive metabolic panel) * CT scan of the abdomen * MRI of the abdomen * Stool examination for the cause of diarrhea and electrolyte levels * Vasoactive intestinal peptide (VIP) level in the blood<ref name="auto"/>
==Treatment== The first goal of treatment is to correct dehydration. Fluids are often given intravenously to replace those lost during diarrhea. The next goal is to slow the diarrhea. Some medications can help control it. Octreotide, an artificially synthesized form of somatostatin (a naturally occurring hormone), blocks the action of VIP.{{citation needed|date=August 2020}}
The best chance for a cure is surgery to remove the tumor. If the tumor has not spread to other organs, surgery can often achieve this.{{citation needed|date=August 2020}}
For metastatic disease, peptide receptor radionuclide therapy (PRRT) can be highly effective. This treatment involves attaching a radionuclide (Lutetium-177 or Yttrium-90) to a somatostatin analogue (octreotate or octreotide). This is a novel way to deliver high doses of beta radiation to eradicate tumours. Some patients seem to respond to a combination chemotherapy consisting of capecitabine and temozolomide, but there is no report stating its curative effects.{{citation needed|date=March 2019}}
==Prognosis==
Surgery can usually serve as the cure. However, in one-third to one-half of patients, the tumor has metastasized to other organs by the time of diagnosis and cannot be cured, only treated.{{citation needed|date=March 2019}}
==References== {{reflist}} {{refbegin}} *{{cite book |last=Jensen |first=R.T. |last2=Norton |first2=J.A. |chapter=32. Endocrine tumors of the pancreas and gastrointestinal tract §VIPomas |chapter-url={{GBurl|zEZOqB6r9hwC|dq=VIPomas|p=508}} |editor-last=Feldman |editor-first=M. |editor2-last=Friedman |editor2-first=L.S. |editor3-last=Brandt |editor3-first=L.J. |title=Sleisenger and Fordtran's Gastrointestinal and Liver Disease |publisher=Saunders Elsevier |edition=9th |date=2010 |isbn=978-1-4377-2767-8 |pages=508–511 }} *{{cite web |title=VIPoma |work=Health Guide |publisher=New York Times |date=December 28, 2010 |archive-date=2013-02-25 |archive-url=https://web.archive.org/web/20130225102140/http://health.nytimes.com/health/guides/disease/vipoma/overview.html |url=http://health.nytimes.com/health/guides/disease/vipoma/overview.html}} {{refend}}
== External links == {{Medical resources | DiseasesDB = 13877 | ICD10 = {{ICD10|C|25|4|c|15}} or {{ICD10|E|16|8|e|15}} | ICD9 = | ICDO = {{ICDO|8155|3}} | OMIM = | MedlinePlus = 000228 | eMedicineSubj = med | eMedicineTopic = 2379 | eMedicine_mult = {{eMedicine2|med|2399}} {{eMedicine2|ped|2428}} | MeshID = D003969 | SNOMED CT = 447643008 | Orphanet = 97282 }} {{Tumor morphology}} {{Endocrine gland neoplasia}}
Category:Endocrine neoplasia Category:Rare cancers Category:Syndromes